New smallpox vaccine tested for safety and immune boost
NCT ID NCT00437021
Summary
This study tested a new smallpox vaccine called IMVAMUNE to see how safe it is and how well it triggers the body's immune defenses. It involved 226 healthy adults who had never received a smallpox vaccine before. Researchers compared different dosing schedules and tracked side effects and immune responses for over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALLPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University - John T. Carey Special Immunology Unit
Cleveland, Ohio, 44106-3808, United States
-
Duke Translational Medicine Institute - Clinical Vaccine Unit
Durham, North Carolina, 27704-2120, United States
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
University of Iowa - Vaccine Research and Education Unit
Iowa City, Iowa, 52242-2600, United States
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
-
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases
Rochester, New York, 14642-0001, United States
-
University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston
Galveston, Texas, 77555-5302, United States
Conditions
Explore the condition pages connected to this study.